6:34 PM
 | 
Oct 31, 2012
 |  BC Extra  |  Company News

FDA reviewers: raxibacumab has 'clinically meaningful benefit'

FDA reviewers said raxibacumab from Human Genome Sciences Inc. has a "positive" benefit-risk profile for treating inhalational anthrax. The human mAb against Bacillus anthracis protective antigen was developed under the FDA Animal Rule, which allows for marketing approval to be granted based on efficacy in relevant animal models and an acceptable safety risk profile in humans. The reviewers noted that in pivotal studies in...

Read the full 310 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >